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ABSTRACT:  38 
Tuberous sclerosis complex (TSC) is a rare disease caused by mutations in the TSC1 39 
or TSC2 genes and is characterized by widespread tumour growth, intractable epilepsy, 40 
cognitive deficits and autistic behaviour. CBD has been reported to decrease seizures and 41 
inhibit tumour cell progression, therefore we sought to determine the influence of CBD on 42 
TSC pathology in zebrafish carrying a nonsense mutation in the tsc2 gene. 43 
CBD treatment from 6 to 7 days post-fertilization (dpf) induced significant anxiolytic 44 
actions without causing sedation. Furthermore, CBD treatment from 3 dpf had no impact on 45 
tsc2-/- larvae motility nor their survival. CBD treatment did, however, reduce the number of 46 
phosphorylated rpS6 positive cells, and their cross-sectional cell size. This suggests a CBD 47 
mediated suppression of mechanistic target of rapamycin (mTOR) activity in the tsc2-/- larval 48 
brain. 49 
3 
Taken together, these data suggest that CBD selectively modulates levels of 50 
phosphorylated rpS6 in the brain and additionally provides an anxiolytic effect. This is 51 
pertinent given the alterations in mTOR signalling in experimental models of TSC.  52 
Additional work is necessary to identify upstream signal modulation and to further justify the 53 
use of CBD as a possible therapeutic strategy to manage TSC. 54 
 55 
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1. INTRODUCTION: 61 
Tuberous sclerosis complex (TSC) is a rare genetic disease caused by a mutation in 62 
the TSC1 or TSC2 genes, coding for the proteins hamartin and tuberin, respectively [1]. TSC1 63 
and TSC2 form an inhibitory complex with GTPase-activating protein (GAP) activity. This 64 
keeps Ras homolog enriched in brain (Rheb) bound to GDP and in an inactive form, 65 
preventing downstream phosphorylation of mechanistic target of rapamycin (mTOR). In 66 
humans and animal models of TSC, mutations in TSC1 or TSC2 impair the inhibitory 67 
function of the complex, allowing activation of Rheb by GTP and constitutive activation of 68 
mTOR [2,3].  69 
mTOR is a major convergence point for extracellular signalling, through regulation of 70 
anabolic processes such as transcription and translation [4]. This regulation of protein 71 
synthesis by mTOR extends throughout the mammalian lifespan and is crucial for central 72 
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nervous system (CNS) development, where it controls soma size, dendritic arborisation, 73 
cortical lamination, and plasticity [5,6]. 74 
Overactivation of mTOR is evident in the majority of TSC patients that present with 75 
benign tumours in several organs, such as skin, kidneys and brain [6,7]. These often require 76 
surgical treatment and are a major source of morbidity for patients [8]. Furthermore, 77 
disruption of mTOR function in TSC also leads to neurological and neuropsychiatric 78 
complications in 85% of patients. Brain lesions such as cortical dysplasia, subependymal 79 
nodules and tubers are present in 70-90% of these patients [1]. Importantly, tubers and the 80 
perituberal tissue have long been associated with epilepsy, the most common neurological 81 
manifestation in TSC. In fact, 80-96% of patients have epilepsy with two thirds refractory to 82 
existent therapies [1,9]. Failure to control seizures in TSC patients is highly correlated with 83 
an early onset of seizures, before the age of 1 year old, in the form of focal epilepsy and 84 
infantile spasms [10]. Epilepsy is frequently associated with tuberous sclerosis associated 85 
neuropsychiatric disorders (TAND), such as autism spectrum disorder, present in 40-50% of 86 
patients, and intellectual disability, present in 30% [9,11]. The importance of seizure control 87 
is further reinforced by its positive impact on developmental outcomes and quality of life 88 
assessments [12,13]. Nonetheless, despite the availability of some treatment options, due to 89 
the high heterogeneity of manifestations and TSC phenotype, not all individuals respond to 90 
the currently available therapies and new options are needed to attend to the patients’ needs 91 
[10,14,15]. 92 
Given that a vast array of different systems and organs are affected by TSC, treatment 93 
typically requires a poly-pharmacological approach. mTOR inhibitors, such as rapamycin and 94 
everolimus, are current first-line treatments to control the growth of asymptomatic lesions. 95 
Epilepsy treatment can include one or multiple anti-epileptic drugs (AEDs), especially if 96 
resistance is present. Vigabatrin, which has been proposed to modulate both GABA levels 97 
5 
and the mTOR pathway [16], displays good efficacy in TSC and is the most commonly used 98 
AED in these patients [9,17]. Regarding TAND, no specific therapies are yet approved, 99 
although early-intervention neuropsychiatric programmes, seizure control and mTOR 100 
inhibition have shown to contribute to cognitive improvement [9,18]. 101 
There is growing evidence to support the use of cannabidiol (CBD), the most 102 
abundant non-euphoric phytocannabinoid derived from Cannabis sativa [19], in the 103 
management of seizures [20]. Previous in vitro and in vivo studies have demonstrated the 104 
efficacy of CBD in reducing the frequency and severity of seizures, in different models of 105 
epilepsy [21,22]. More recently, two clinical trials provided evidence of a CBD induced 106 
reduction in the median frequency of convulsive seizures and of drop seizures, in Dravet 107 
Syndrome (DS) and Lennox-Gastaut Syndrome, respectively [23,24]. Additionally, an 108 
expanded-access study of CBD for patients with TSC also suggested an effect of CBD in 109 
reducing seizure frequency in this population [25]. CBD has also shown beneficial effects in 110 
tumour studies. In vitro reduction of cellular viability and proliferation was demonstrated in 111 
both tumour cell lines [26–31] and primary tumour cells [26], whilst reducing tumour volume 112 
[26,28,31] and metastasis in vivo [31–33]. Importantly, CBD has been shown to modulate 113 
some components of the mTOR pathway [30,31,34–38], however there is a divergence in the 114 
reported effects with evidence from the cancer field supporting a CBD inhibition of mTOR, 115 
while epilepsy studies indicate an activation of mTOR. Therefore, in the complex pathology 116 
of TSC, the modulation of mTOR signalling via CBD is unclear. 117 
Several animal models are available for the study of TSC, although none of these 118 
fully replicates all features of the human disease [39]. Mammalian models include the Eker 119 
rat, with a spontaneous Tsc2 mutation, and several conditional knockout mice which allow 120 
biallelic inactivation of Tsc1 or Tsc2 in a cell specific manner [39,40]. Non-mammalian 121 
models are also widely used, as it is the case of Saccharomyces cerevisiae, Drosophila and 122 
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zebrafish [41]. The zebrafish model of TSC used here carries the nonsense vu242 mutation in 123 
the tsc2 gene [42]. This renders tuberin inactive as it lacks the functional GAP domain. 124 
Several human-like disease features, such as increased phosphorylation of rpS6, a protein 125 
downstream of mTOR and often used as a readout of mTORC1’s activity [43,44], increased 126 
cell size and early death of homozygotes, are present in this model [42]. More recently, an 127 
mTOR-dependent disruption of locomotor behaviour was also demonstrated in homozygous 128 
tcs2-/- larvae [45]. Here we use a zebrafish model of TSC to examine the effects of CBD on 129 
the pathogenesis of TSC, including behavioural effects and ribosomal protein 6 130 
phosphorylation. Our data highlights that CBD can modulate the mTOR pathway, through 131 
regulating the phosphorylation status of ribosomal protein 6 in a relevant model of TSC.   132 
 133 
2. MATERIALS AND METHODS: 134 
Zebrafish Husbandry 135 
Zebrafish embryos, heterozygous for the tsc2vu242 mutation backcrossed with Tupfel 136 
longfin wild-type fish, were a generous gift of Malgorzata Wiweger, head of the Zebrafish 137 
Core Facility of the International Institute of Molecular and Cell Biology (Warsaw, Poland). 138 
The zebrafish model of TSC with a tsc2 nonsense mutation (tsc2+/-) was previously described 139 
[42,45]. For this study, heterozygous (tsc2+/-) zebrafish were interbred to generate a mixture 140 
of wild-type (tsc2+/+), heterozygous (tsc2+/-) and homozygous (tsc2-/-) larvae. Adult zebrafish 141 
were maintained at 28.5 °C in UV-sterilized water on a 14 h light/10 h dark cycle under 142 
standard aquaculture conditions. Fertilized eggs were collected via natural spawning. 143 
Embryos and larvae (tsc2+/+, tsc2+/- and tsc2-/-) were raised in embryo medium, containing 1.5 144 
mM HEPES, pH 7.6, 17.4 mM NaCl, 0.21 mM KCl, 0.12 mM MgSO4 and 0.18 mM 145 
Ca(NO3)2 in an incubator on a 14 h light/10 h dark cycle at 28.5 °C. For all experiments 146 
described, larvae from 0 to 10 days post-fertilization (dpf) were used. All zebrafish 147 
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experiments were approved by the Ethics Committee of the University of Leuven (Ethische 148 
Commissie van de KU Leuven, approval number 061/2013) and by the Belgian Federal 149 
Department of Public Health, Food Safety and Environment (Federale Overheidsdienst 150 
Volksgezondheid, Veiligheid van de Voedselketen en Leefmilieu, approval number 151 
LA1210199). 152 
 153 
Maximum Tolerated Concentration (MTC) 154 
6 dpf larvae were placed in a 24 well-plate (Corning Inc., New York, USA) and 155 
incubated with 396 µL of swimming medium (Danieau’s) and 4 µL DMSO (0.1 or 1%) or 156 
CBD (GW Pharmaceuticals, Cambridge, UK) dissolved in DMSO. CBD was serial diluted 157 
and tested in concentrations ranging from 0.3 µM to 125 µM. Plates were then transferred to 158 
a 37 ˚C incubator, in the dark, and larvae touch-response was tested after 1 and 24 hours of 159 
incubation. The MTC was defined as the highest concentration of CBD in DMSO that did not 160 
induce any observable signs of toxicity, such as necrosis, abnormal heart beat or loss of 161 
posture [46]. 162 
 163 
Locomotor Assay 164 
The locomotor assay was performed as previously published [45]. In brief, 6 dpf 165 
larvae were placed in a 24 well-plate, treated with Danieau's (called naïve larvae in the text), 166 
0.1% DMSO or 1.25 µM CBD in 0.1% DMSO, and incubated in dark for 24 hours. Plates 167 
were then removed from the incubator and placed in a Zebrabox, where movement of the 168 
larvae was automatically tracked and expressed in "actinteg" units (which is the sum of pixel 169 
changes detected during tracking). Here, fish were habituated for 10 minutes under both light 170 
and dark condition before being tracked for 5 minutes in both the light and dark conditions. 171 
To measure anxiogenic or anxiolytic effects due to compound administration, changes in the 172 
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startle response upon light to dark transition were measured as previously published [47,48]. 173 
Touch response (TR) can be used to corroborate the MTC data as it is also a measure of 174 
larval peripheral reflexes [49]. Touch-response was tested, by touching the larvae’s tail with a 175 
blunt needle, before and after tracking to monitor toxicity. The number of responding and 176 
non-responding larvae was registered. All researchers were blinded to genotype throughout 177 
behavioural testing and data analyses. 178 
 179 
Chronic Treatment and Survivability Assay 180 
Larvae were cultured in 200 µl of Danieau’s, in a 96-well plate, and followed from 3 181 
dpf until 10 dpf. Medium was changed every other day and 0.1% DMSO or 1.25 µM CBD in 182 
0.1% DMSO added to the wells. The number of dead larvae was counted daily. At the end of 183 
the assay, the surviving larvae underwent the previously described locomotor assay. 184 
 185 
Genotyping 186 
Genotyping was conducted as previously published [45]. In summary, after sacrifice, 187 
zebrafish tails were collected and lysed for 3 hours, at 55 ˚C, followed by 10 minutes at 95 188 
˚C. PCR was performed on the lysates using Pfu polymerase (Thermo Scientific, UK), and 189 
the primers GTAACACAGAATCAGTGAATCGGA (forward primer) and 190 
CACACACAGAAAACACTTGAAGC (reverse primer). After PCR, samples underwent 191 
digestion with HpyCh4 IV (New England Biolabs, UK), for 1 hour, at 37 ˚C, followed by 192 
fragment separation on a 2% agarose/ 0.5 µg/mL ethidium bromide gel, for 1 hour, at 110 V.  193 
Due to post-mortem genotyping, and because a smaller ratio of tsc2-/- larvae is obtained 194 
compared to tsc2+/+ and tsc2+/-, variation in group sizes exists throughout experiments. 195 
 196 
Immunohistochemistry (IHC) 197 
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After completion of the locomotor assay, 7 dpf zebrafish larvae were sacrificed in ice 198 
cold water. Heads were dissected and placed in 4% PFA for 48 hours, at 4 ˚C, and then 199 
transferred into a 30% sucrose in PBS solution, at 4 ˚C. These were then embedded in 200 
optimum cutting temperature (OCT) compound and stored at -80 ˚C until sectioned. 10 µm 201 
sections were cut and collected onto microscope slides (SuperFrost Plus, Thermo Fisher 202 
Scientic, UK) and stored at -80 ˚C until used. 203 
For IHC, sections were incubated for 2 hours, at room temperature, in a 2% BSA, 204 
10% horse serum and 0.05% TX-100 buffer, followed by an overnight incubation with a 205 
primary antibody against phosphorylated rpS6 (Ser235/236) (1:500; 2211 New England 206 
Biolabs, lot 0023, UK), in a 1 % BSA and 0.05% TX-100 buffer, at 4 ˚C. The next day, slides 207 
were rinsed in Tris-buffered saline (TBS) and incubated for 2 hours, at room temperature, 208 
with a goat anti-rabbit Alexa Fluor-647 secondary antibody (1:1000; A-21245 Thermo Fisher 209 
Scientific, lot 1805235, UK). After further rinses, sections were counterstained with DAPI 210 
(1:10 000; D1306 Thermo Fisher Scientific, UK) for 10 minutes, rinsed, dried, and mounted. 211 
For TUNEL staining (1:10; 12156792910 Roche, lot 26320800, Sigma, UK), slides 212 
underwent the same buffer incubation procedure, excluding antibody incubation. After the 213 
final rinsing step, sections were incubated with TUNEL solution, in the dark, for 1 hour, at 37 214 
˚C. Negative control was done by omitting the enzyme solution, while positive control was 215 
performed by previous incubation of sections with 5 mg/mL DNAse, for 10 minutes, at 37 216 
˚C. 217 
 218 
Imaging and Image quantification 219 
Non-consecutive brain sections were imaged using a Zeiss AxioImager microscope. 220 
Exposure time was constant during image acquisition and background fluorescence was 221 
measured where the primary antibody or enzyme solution was omitted. Pictures were taken 222 
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with a 20x objective using the AxioVision software. Original images were processed on Fiji 223 
Image J [50], and a region of interest (ROI) was freehand defined around the brain outline. 224 
The average intensity value for each ROI, in each picture, was measured as Intensity 225 
Arbitrary Units (IAU), following background subtraction for each picture. For cell counting, 226 
cells were considered positive if staining for both phosphorylated rpS6 and DAPI were 227 
clearly present. To measure cell size, a similar procedure was used, except five cells per 228 
picture were randomly selected and its cross-sectional area measured. A minimum of three 229 
animals per group and genotype were used, and 3-9 sections per animal were imaged and 230 
counted.  231 
 232 
Statistical Analysis 233 
Statistical analysis was performed in SPSS (IBM SPSS Statistics 22) and GraphPad 234 
Prism 5. Repeated measures two-way ANOVA was used to analyse data from the locomotor 235 
assay (genotype x treatment x exposure to light/dark) and phosphorylated rpS6 positive cell 236 
number (genotype x treatment x number positive cells/section), while a three-way ANOVA 237 
was used to analyse cell size (genotype x treatment x area of cells). Touch response (TR) (yes 238 
x no) was analysed by chi-square test and TUNEL positive cells with the Kruskal- Wallis 239 
test. Normality was assessed with the D'Agostino-Pearson omnibus test. Statistical testing 240 
was followed by Tukey or Bonferroni post-hoc tests. 241 
Data are expressed as mean ± SEM unless stated otherwise, and significant values were 242 
considered when p≤0.05. All graphs were prepared with GraphPad Prism 5. 243 
 244 
3. RESULTS 245 
3.1. CBD safety profile 246 
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To determine the maximum tolerated concentration (MTC) to be used in further 247 
experiments, CBD and DMSO were tested at different concentrations, ranging from 0.3 µM 248 
to 125 µM CBD in DMSO, and 0.1% to 1% respectively. 249 
Concentrations from 5 to 125 µM CBD in 1% DMSO, induced varying levels of 250 
toxicity in the larvae, manifested by slow heartbeat, loss of posture and death. We then 251 
compared lower CBD concentrations (0.3 to 2.5 µM) in 0.1 or 1% DMSO. Here, the toxicity 252 
of CBD was reduced with the decrease in DMSO concentration from 1% to 0.1%. 1.25 µM 253 
CBD in 0.1% DMSO was the highest CBD concentration in which all animals were alive 254 
after 24 hours and showed no signs of gross morphological abnormalities. 255 
At a cellular level, toxicity signs were absent from the central nervous system, as 256 
indicated by a non-significant difference (p=1.0) in the number of apoptotic cells, as 257 
indicated by positive TUNEL staining (Fig. 1A-C). 258 
Regarding touch-response, compared to both the Danieau’s and 0.1% DMSO treated 259 
groups, administration of CBD from 6 to 7 dpf did not affect the percentage of responders to 260 
touch (χ2(2)=2.51, p=0.3; 98.0% for Danieau’s, n=155; 95.8% for 0.1% DMSO, n=166; 261 
94.7% for CBD, n=171), as manifested by a non-significant difference in the TR of treated 262 
larvae (Fig.2A). 263 
 264 
3.2.Behavioural effects of CBD  265 
3.2.1. CBD does not induce sedation in this zebrafish TSC model 266 
Next, we analysed larvae locomotor behaviour. To test the reported sedative 267 
properties of CBD [23,25], we quantified the average swimming movement of larvae during 268 
the light period, as a reduction of overall exploratory movement can be used as a measure of 269 
sedation [51,52]. There were no statistically significant differences in the baseline 270 
behavioural exploration, between vehicle (0.1% DMSO, 24h incubation) and CBD (1.25 µM, 271 
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24 hour incubation) treated larvae (F(1,322)=2.28, p= 0.1), in the tsc2+/+ (2275.9 ± 190.3 272 
actinteg units, n=63 vs 1914.7 ± 289.1 actinteg units, n=49, p=0.873), tsc2+/- (2349.3 ± 241.7 273 
actinteg units, n=76 vs 1907.3 ± 158.2 actinteg units, n= 92, p=0.338) and tsc2-/- (906.1 ± 274 
208.3 actinteg units, n=26 vs 732.5 ± 159.1 actinteg units, n=22, p=1.00) groups, indicating 275 
that, under these conditions, CBD does not induce sedation (Fig. 2B). 276 
 277 
3.2.2. CBD reduces startle response of zebrafish larvae during the dark period 278 
Zebrafish larvae respond to changes in light beginning from 5 dpf [53,54], and sudden 279 
changes from light to dark induce a startle response. Decreased locomotion after a startle 280 
stimulus is indicative of an anxiolytic effect [52,53,55–57]. Here, CBD (1.25 µM, 24 hour 281 
incubation) treatment significantly reduced dark-induced movement compared to 0.1% 282 
DMSO (F(1,322)=7.26, p=0.01) for all genotypes (Fig.2C).  283 
 284 
3.2.3. CBD does not rescue homozygote behavioural phenotype  285 
One of the features of this model is early death of tsc2-/- homozygotes, between 9 and 286 
11 dpf [42,45]. This can also be seen in other TSC model organisms, such as mice and rats, 287 
which typically die at embryonic day 10-10.5 [58–60]. Additionally, reduced overall 288 
locomotion was recently shown in tsc2-/- larvae [45]. We therefore assessed the effects of 289 
long-term CBD incubation, from 3 to 10 dpf, on survivability and locomotion. No difference 290 
in the survival of tsc2-/- larvae (χ2(1)=0.27, p=0.6; n= 72 per group) (Fig.3A) nor swimming 291 
ability (t(1)=3.06, p=0.2; 1459.8 ± 366.8 actinteg units, n=28, vs 2875.6 ± 520.1 actinteg 292 
units, n=27) (Fig.3B) was found between 0.1% DMSO and CBD treated groups. 293 
 294 
3.3. CBD modulates phosphorylated rpS6  295 
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3.3.1. CBD reduces the number of phosphorylated rpS6 positive cells in tsc2+/+, 296 
tsc2+/- and tsc2-/- larvae 297 
We subsequently assessed the impact of CBD treatment upon rpS6 phosphorylation, 298 
which is increased in tsc2-/- zebrafish [42,45]. In the Danieau’s group, we observed increased 299 
phosphorylated rpS6 immunofluorescence in tsc2-/- zebrafish brains (18.0 ± 2.0 IAU), 300 
compared to the tsc2+/+ (8.0 ± 1.1 IAU) and tsc2+/- (8.4 ± 1.3 IAU) groups, confirming what 301 
others had previously shown [42,45]. Unexpectedly, an overall increase in phosphorylated 302 
rpS6 intensity was also observed in sections from 0.1% DMSO incubated larvae (10.72 ± 1.7, 303 
for tsc2+/+, 6.0 ± 0.6, for tsc2+/-, 12.1 ± 1.4 IAU, for tsc2-/-), while reduced 304 
immunofluorescence was found in the CBD groups (4.5 ± 0.6, for tsc2+/+, 6.0 ± 0.9, for tsc2+/-305 
, 11.09 ± 1.2, for tsc2-/- IAU) (Fig.4A). 306 
Section size was accounted for by prior analysis of total brain section size. This 307 
revealed no significant differences between genotypes or treatments (Fig.1D). 308 
Quantification of phosphorylated rpS6 positive cells revealed a significant main effect 309 
of treatment, indicating that 0.1% DMSO on its own increased the number of phosphorylated 310 
rpS6 positive cells per section (187.1 ± 13.6 cells per section) compared to Danieau’s (116.1 311 
± 11.7 cells per section) and to CBD (42.8 ± 13.0 cells per section). Considering genotype-312 
specific effects, further analysis revealed that 0.1% DMSO significantly increased the 313 
number of phosphorylated rpS6 positive cells in the tsc2+/+ group, while this increase was not 314 
evident in the tsc2+/- and tsc2-/- group. CBD suppressed the DMSO-induced increase in the 315 
number of phosphorylated rpS6 positive cells across all genotypes (184.1 ± 26.0, n=12 vs 316 
10.7 ± 19.6, n=21, p<0.001; 97.7 ± 23.2, n=15 vs 3.2 ± 26.0, n=12, p=0.03; 279.3 ± 21.2, 317 
n=18 vs 114.7 ± 21.2, n=18 p<0.001; for tsc2+/+, tsc2+/- and tsc2-/- larvae, respectively) 318 
(Fig.4C).  319 
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Taken together, this data suggests that CBD led to a reduction of phosphorylated rpS6 320 
immunoreactivity in larval brain. 321 
 322 
3.3.2. CBD reduces the size of phosphorylated rpS6 positive cells in tsc2+/+, tsc2+/- 323 
and tsc2-/- larvae 324 
The phosphorylation status of rpS6 has been correlated with cell size [37,61], 325 
therefore we measured the cross-sectional area of phosphorylated rpS6 positive cells in the 326 
brain (Fig.4B). 327 
A genotype dependent increase in cell area was seen in the naïve group. That is, cells 328 
from tsc2+/- sections were larger than tsc2+/+ (22.5 ± 0.6 µm2, n=133 vs 19.3 ± 0.5 µm2, 329 
n=165; p<0.001), while tsc2-/- cells were also larger compared to tsc2+/- (28.3 ± 0.6 µm2, 330 
n=105 vs 22.5 ± 0.6 µm2, n=133; p<0.001) (Fig. 4D). Therefore, while a difference in the 331 
number of phosphorylated rpS6 positive cells between the naïve tsc2+/+ and tsc2+/- larvae was 332 
absent, here, the area of cells from heterozygote and wild-type animals did differ. Regarding 333 
CBD incubated larvae, these had smaller phosphorylated rpS6 positive cells than the ones 334 
present in the 0.1% DMSO group (Fig.4C). This effect was seen across tsc2+/+ (22.8 ± 0.7 335 
µm2, n= 95 vs 18.0 ± 0.6 µm2, n=129; p<0.001), tsc2+/- (19.9 ± 0.6 µm2 n=115 vs 16.3 ± 0.6 336 
µm2 n=77; p=0.001) and tsc2-/- larvae (27.4 ± 0.6 µm2, n=115; 21.7 ± 0.6 µm2, n=144; 337 
p<0.001) (Fig.4D). Similar to results seen for cell number, where an effect of 0.1% DMSO 338 
was reported, a DMSO-driven increase in cell size was also observed here (Fig.4D). This was 339 
also significantly supressed by CBD incubation. Altogether, these data indicate that CBD 340 
reduces genotype and DMSO- induced increase of size in tsc2+/- and tsc2-/- zebrafish brain 341 
cells. 342 
 343 
4. DISCUSSION 344 
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CBD is a non-psychoactive component of Cannabis, that has increasingly been 345 
recognised as the basis for pharmacology intervention in a host of diseases [19,20,62]. Here 346 
we examine the effects of CBD to modulate aberrant mTORC1 signalling in zebrafish 347 
carrying a tsc2 mutation. 348 
Anxiety is a TSC-associated neuropsychiatric disorder and evidence indicates altered 349 
serotonin signalling as a biological mechanism [65-68]. One of the proposed targets for CBD 350 
is the 5-HT1A receptor, where it has been shown to bind and to have agonist functions at 351 
concentrations ≥10 µM in vitro [73,74]. Several serotonin receptors, orthologues to human 352 
receptors, have been shown to be expressed in zebrafish larvae, including the 5-HT1A receptor 353 
[72,79]. This is pertinent to the current study with the 5-HT1A receptor a proposed site of 354 
action for CBD [73,74]. However, contrasting with the function of mammalian 5-HT1A 355 
receptors, the role of these receptors on anxiety behaviour in zebrafish is less defined. For 356 
example, extracellular serotonin content has been reported to have contrasting effects on 357 
anxiety in the same adult zebrafish species [72,80]. Larvae, in contrast to their adult 358 
counterparts, exhibit a transient elevation in motor activity in response to sudden onset of 359 
darkness [53,64,81]. Dark avoidance was shown to be modulated by anxiolytic drugs such as 360 
the 5-HT1A agonist, buspirone, which increased dark preference patterns in zebrafish larvae 361 
[81]. 362 
Here we demonstrate a CBD induced reduction in startle response across genotypes 363 
However, a limitation of this model is that tsc2-/- larvae do not reach adulthood and, 364 
therefore, later behavioural testing cannot be performed to confirm an anxiolytic effect of 365 
CBD in this genotype. Nonetheless, further studies in tsc2+/- larvae could still be beneficial to 366 
elucidate possible effects of CBD in TSC, given the clinical TSC population are heterozygous 367 
[7]. 368 
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Several molecular processes have been proposed to modulate CBD actions [19]. The 369 
serotonergic system is one such example and modulation here could provide control of other 370 
TSC features such as epilepsy, highly prevalent in TSC patients [17]. Evidence from epilepsy 371 
studies indicates that a reduction in serotonin concentration promotes seizures, while reduced 372 
serotonin binding to the 5-HT1A receptor has been reported in epileptogenic foci [83,84]. 373 
Studies also indicate that TSC patients present with increased tryptophan uptake localised to 374 
epileptic foci [85]. Given that CBD has been shown to reduce seizures in pathologies with 375 
different aetiologies [23,25,89], and that tsc2-/- zebrafish, and other TSC models, have been 376 
shown to exhibit abnormal brain activity [45,90–92], it would be relevant to further study its 377 
role in the serotonergic system of TSC models.  378 
A hallmark of TSC across all experimental models is an increase in mTOR activity 379 
[1,3,5,6,42,45]. Activation of mTOR leads to an increase in the ratio of downstream targets 380 
phosphorylated rpS6 /total rpS6, both in in vitro and in vivo models [88,91,95,96]. Therefore, 381 
phosphorylated rpS6 is often used as a read out of mTOR activation [97–99]. The reduction 382 
of rpS6 phosphorylation presented here is in line with published work where CBD treatment 383 
was found to modulate the mTOR pathway. In breast cancer cells, incubation with CBD has 384 
been observed to modulate Akt, a kinase upstream of mTOR, as well as 4E-BP1 and cyclin D 385 
[30,31]. Another study also reported the reduction of ERK phosphorylation, a kinase 386 
upstream of mTOR [31]. The effects observed here with 0.1% DMSO may indicate a 387 
proinflammatory response [101-103] with subsequent activation on mTOR [104,105]. 388 
The mTOR-S6K-S6 axis is also known to have a major role in controlling cell size 389 
[98,106]. In fact, we saw that Danieau’s incubated animals showed a mutation-dependent 390 
increase in cell size, with tsc2-/- brain cells bigger than tsc2+/-, followed by tsc2+/+. These 391 
results are similar to previous work on this model, where a difference in size was found 392 
between tsc2+/+ and tsc2-/-, in liver, brain, and spinal cord cells [42]. In accordance with a 393 
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reduction in phosphorylated rpS6 positive cells there was a corresponding CBD effect on the 394 
cross-sectional area of brain cells. A comprehensive analysis of mTOR activity in 395 
phosphorylated rpS6 cells through enzymatic assay would definitely link the disruption in 396 
phosphorylated rpS6 to mTOR activity which remains unresolved in this current study.  397 
However, contrasting effects on the mTOR signalling pathway by CBD have also 398 
been reported. For example, in amphetamine-sensitized rats, CBD reduced levels of pGSK-399 
3β and pAkt, but importantly it induced an increase of pmTOR and pS6K [35]. To further 400 
demonstrate the effect of CBD on mTOR specifically, this effect was reversed with the 401 
mTOR inhibitor, Torin 2 [35]. Additionally, administration of 10 mg/kg CBD to a mouse 402 
model of multiple sclerosis revealed increased pPI3K, pAkt, pmTOR and pS6K in spinal cord 403 
tissue. Importantly, in this model, basal levels of mTOR pathway activation were shown to be 404 
decreased [36]. Regarding the zebrafish model used here, we observed a decrease in 405 
phosphorylated rpS6, which could result from a reduction in mTOR activation. However, the 406 
survival and locomotion data regarding the chronically CBD-treated tsc2-/- larvae highlight 407 
that this modulation of mTOR was insufficient to impact these whole system outputs. 408 
 409 
5. CONCLUSION 410 
In the current study, using a TSC zebrafish model, we demonstrate that CBD was 411 
tolerable, while behavioural testing showed that CBD exhibited an anxiolytic profile without 412 
sedative effects. Additionally, we showed modulation of rpS6 manifested by the reduction of 413 
the number and size of phosphorylated rpS6 positive cells in the brain. Altogether, these data 414 
demonstrate that CBD modulates aberrant mTOR signalling in a model of TSC. It provides a 415 
rationale for further investigation into CBD as a therapeutic agent in diseases where mTOR 416 
signalling is disrupted.  417 
 418 
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Figures 793 
 794 
 795 
Figure 1: TUNEL labelling in the larval brain. (A) Representative pictures of the midbrain, for each 796 
treatment (Danieau’s, 0.1% DMSO and 1.25 µM CBD) and genotype (tsc2+/+, tsc2+/- and tsc2-/-), showing 797 
TUNEL positive cells in red and tissue autofluorescence in green. (B) Representative pictures of negative 798 
control, where enzyme solution was omitted, and of positive control, incubated with DNAse. (C) Median 799 
number of TUNEL positive cells in each section analysed, showing no statistical differences between treatment 800 
groups. (n=3 animals per group; p=1.0. Data shown as median and minimum to maximum values) (D) 801 
Measurement of brain sections’ area showed no significant differences in cross-sectional size, regardless of 802 
genotype (F(2,209)=0.30, p=0.7) or treatment (F(2,209)=2.92, p=0.06) (n= 3-4 animals per group, 15-30 803 
sections per group measured). Scale=50 µm. 804 
 805 
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 806 
Figure 2: Treatment and genotype effects on larval locomotor behaviour: (A) Zebrafish touch-response is 807 
not altered in the presence of 0.1% DMSO nor CBD. Pooled data demonstrating no significant differences 808 
(χ2(2)=2.5, p= 0.3) between the percentage of zebrafish responding to touch in each treatment group (n=152 for 809 
Danieau's, n=165 for 0.1% DMSO, n=163 for CBD). Values are shown as percentage of "Yes" or "No" 810 
response. (B) CBD has no effect on locomotor activity during light phase. Actinteg units normalised to vehicle 811 
(0.1% DMSO) values demonstrate lack of effect on swimming activity under light (F(1,322)=2.28, p= 0.1), 812 
following exposure to CBD, indicating the absence of sedating properties (n= 49-63 for tsc2+/+, n=76-92 for 813 
tsc2+/-, n= 22-26 for tsc2-/-). (C) CBD reduces zebrafish locomotor activity after a dark startling stimulus. 814 
Exposure to CBD during the light period (light bars) did not alter the average larval movement in any genotype. 815 
In the presence of a dark startling stimulus (dark bars), CBD induced a reduction of the average swimming 816 
activity (F(1,322)=7.26, p=0.01)  Values are shown as mean actinteg units ± SEM, ***p<0.001, **p<0.01, 817 
*p<0.05 818 
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 819 
 820 
Figure 3: CBD does not improve tsc2-/- larvae survival nor rescues movement deficits. (A) Treatment with 821 
1.25 µM CBD, from 3-10 dpf, did not alter tsc2-/- larvae survival compared to vehicle (n=72 per group). (B) 822 
CBD treatment from 3-6 dpf CBD did not modulate movement deficits in tsc2-/- larvae (t(1)=3.06, p=0.2; 1459.8 823 
± 366.8 vs 2875.6 ± 520.1 actinteg units, n= 28 for 0.1% DMSO and n=27 for CBD, data presented as mean ± 824 
SEM). 825 
  826 
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 827 
Figure 4: CBD reduces the number and size of phosphorylated rpS6 (Ser235/236) positive cells. (A) 828 
Representative pictures of the forebrain of Danieau’s, 0.1% DMSO and CBD incubated larvae. Blue represents 829 
DAPI, green tissue autofluorescence and red phosphorylated rpS6 (Ser235/236) positive cells. (C) 830 
Quantification of the number of phosphorylated rpS6 (Ser235/236) positive cells in larval brain sections. 0.1% 831 
DMSO incubation increased the number of phosphorylated rpS6 (Ser235/236) positive cells in the tsc2+/+ group. 832 
CBD reduced the number of positive cells in all genotypes compared to 0.1% DMSO but only in the tsc2-/- 833 
group, compared to the Danieau’s incubated larvae (F(4,44)=3.14, p=0.02; n= 3-9 sections analysed, from 3-4 834 
animals per group). (B) Magnification of a 0.1% DMSO-treated tsc2+/+ brain section exemplifying how the 835 
cross-sectional area of phosphorylated rpS6 (Ser235/236) positive cells was measured. (D) CBD incubation 836 
31 
induced a reduction of the average cross-sectional area of phosphorylated rpS6 (Ser235/236) positive cells in all 837 
genotypes, compared to 0.1% DMSO (F(4,1050)=9.06, p<0.001; n= 77-115 cells per genotype and treatment 838 
from 3-4 animals per group). Values are shown as mean ± SEM. ***p<0.001, *p<0.05. Scale=50 µm. 839 
 840 
 841 
